{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:09:20Z","timestamp":1777860560444,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-022-02495-z","type":"journal-article","created":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T02:02:20Z","timestamp":1662256940000},"page":"937-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term outcomes of infliximab in patients with Beh\u00e7et's disease-associated uveitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Satoshi","family":"Yamana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunobu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyo","family":"Yawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"issue":"5","key":"2495_CR1","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M (2012) Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol 130(5):592\u2013598","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2495_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol 138(3):373\u2013380","journal-title":"Am J Ophthalmol"},{"key":"2495_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet 358:295\u2013296","journal-title":"Lancet"},{"key":"2495_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/OPTH.S198648","volume":"13","author":"A Katsuyama","year":"2019","unstructured":"Katsuyama A, Kusuhara S, Nishisho R, Matsumiya W, Azumi A, Nakamura M (2019) Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Beh\u00e7et\u2019s disease. Clin Ophthalmol 13:521\u2013527","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"2495_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5152\/eurjrheum.2017.17068","volume":"5","author":"S Ueda","year":"2018","unstructured":"Ueda S, Akahoshi M, Takeda A et al (2018) Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Beh\u00e7et\u2019s disease. Eur J Rheumatol 5(1):9\u201315","journal-title":"Eur J Rheumatol"},{"issue":"6","key":"2495_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-018-4092-4","volume":"37","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Vitale A, Rigante D et al (2018) Predictors of sustained clinical response in patients with Beh\u00e7et\u2019s disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol 37(6):1715\u20131720","journal-title":"Clin Rheumatol"},{"issue":"10","key":"2495_CR7","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","volume":"121","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Kezuka T, Sugita S et al (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et\u2019s disease: a multicenter study. Ophthalmology 121(10):1877\u20131884","journal-title":"Ophthalmology"},{"issue":"6","key":"2495_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","volume":"21","author":"S Al Rashidi","year":"2013","unstructured":"Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM (2013) Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab. Ocul Immunol Inflamm 21(6):468\u2013474","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"2495_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Sota J, Vitale A et al (2019) Ten-year retention rate of infliximab in patients with Beh\u00e7et\u2019s disease-related uveitis. Ocul Immunol Inflamm 27(1):34\u201339","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"2495_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","volume":"26","author":"AM Abu El-Asrar","year":"2005","unstructured":"Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A (2005) Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease. Int Ophthalmol 26(3):83\u201392","journal-title":"Int Ophthalmol"},{"issue":"3","key":"2495_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"M Accorinti","year":"2007","unstructured":"Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P (2007) Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol 51(3):191\u2013196","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"2495_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M et al (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behcet\u2019s disease: a 24-month follow-up study. Rheumatology 46(7):1161\u20131164","journal-title":"Rheumatology"},{"issue":"3","key":"2495_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/09273948.2012.670360","volume":"20","author":"MJ Capella","year":"2012","unstructured":"Capella MJ, Foster CS (2012) Long-term efficacy and safety of infliximab in the treatment of Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm 20(3):198\u2013202","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"2495_CR14","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol 31(7):1362\u20131368","journal-title":"J Rheumatol"},{"issue":"1","key":"2495_CR15","doi-asserted-by":"publisher","first-page":"22227","DOI":"10.1038\/s41598-020-78718-z","volume":"10","author":"N Horiguchi","year":"2020","unstructured":"Horiguchi N, Kamoi K, Horie S et al (2020) A 10-year follow-up of Infliximab monotherapy for refractory uveitis in Beh\u00e7et\u2019s syndrome. Sci Rep 10(1):22227","journal-title":"Sci Rep"},{"issue":"1","key":"2495_CR16","first-page":"66","volume":"28","author":"Y Mizushima","year":"1988","unstructured":"Mizushima Y (1988) Revised diagnostic criteria for Beh\u00e7et\u2019s disease in 1987. Ryumachi 28(1):66\u201370","journal-title":"Ryumachi"},{"issue":"7","key":"2495_CR17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/bjophthalmol-2015-307362","volume":"100","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Murata H, Takamoto M et al (2016) Beh\u00e7et\u2019s disease ocular attack score 24 and visual outcome in patients with Beh\u00e7et\u2019s disease. Br J Ophthalmol 100(7):990\u2013994","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2495_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","volume":"58","author":"T Kaburaki","year":"2014","unstructured":"Kaburaki T, Namba K, Sonoda KH et al (2014) Beh\u00e7et\u2019s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol 58(2):120\u2013130","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"2495_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00417-009-1234-z","volume":"248","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Araki F, Takamoto M et al (2010) Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Beh\u00e7et\u2019s disease. Graefes Arch Clin Exp Ophthalmol 248(5):709\u2013714","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2495_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/annrheumdis-2012-202591","volume":"72","author":"T Dervieux","year":"2013","unstructured":"Dervieux T, Weinblatt ME, Kivitz A, Kremer JM (2013) Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. Ann Rheum Dis 72(6):908\u2013910","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2495_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","volume":"126","author":"J Lin","year":"2008","unstructured":"Lin J, Ziring D, Desai S et al (2008) TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126(1):13\u201330","journal-title":"Clin Immunol"},{"issue":"9","key":"2495_CR22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/2012.jama.10857","volume":"308","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308(9):898\u2013908","journal-title":"JAMA"},{"issue":"11","key":"2495_CR23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med 177(11):1605\u20131612","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2495_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard.2009.121491","volume":"69","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69(7):1286\u20131291","journal-title":"Ann Rheum Dis"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02495-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02495-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02495-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T02:06:58Z","timestamp":1679969218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02495-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["2495"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02495-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,4]]},"assertion":[{"value":"19 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Approval was obtained from the ethics committee of Kyushu University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Nonapplicable due to the retrospective design.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nonapplicable due to the retrospective design.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}